A child growth promoting bi-component complex formula and a method of making the same

Abstract

The application discloses a kind of children growth-promoting two-component composite formula and its preparation method, belong to children nutrition processing technical field, the present application with slow-release short-chain fatty acid precursor, oligogalactose-coated L-glutamine microcapsule, pH-sensitive chitosan carrier loaded trace 5-HT precursor as main raw material preparation leading agent, the leading agent is powder;With calcium-VD3-collagen peptide self-assembly nanoparticle, Zn-Mg-vitamin K2 hydrogel microsphere as main core material preparation capsule type main force agent;Leading agent is packaged in aluminium foil bag by nitrogen filling;Main force agent is packaged using blister packaging technology.The application is compared with the effect of the above-mentioned growth-promoting material and existing direct consumption under the digestive conditions created by leading agent, and the effect is significantly improved.

Description

Technical Field

[0001] The invention belongs to the technical field of children's nutritional product processing, and relates to a children's growth-promoting two-component compound formula and a preparation method thereof. Background Art

[0002] During the golden period of children's growth and development, such as 4-7 years old, appropriate supplementation of growth-promoting substances, such as protein, minerals, vitamins, etc., can help children increase their height and weight; children's spleen and stomach are mature around 6-7 years old, and they can accept a large amount of nutrients, and they are also in the growth and development stage at 6-7 years old; children aged 6-7 are basically students. In order to match children's eating time and eating convenience, growth promoters are generally taken with dairy products for children at breakfast. Actual research has found that most children currently have poor eating and sleeping habits, and they eat within half an hour before going to bed at night. In addition, their metabolism is slow at night, their digestive ability is weak, and there is a gastrointestinal burden, which causes the peristalsis of the digestive tract to become slow when children wake up in the morning. The effect of supplementing growth-promoting substances in the morning is poor, and there is no obvious effect of promoting growth. Summary of the Invention

[0003] The purpose of the present invention is to provide a two-component compound formula for promoting growth in children and a preparation method thereof, so as to solve the problem that existing children's growth promoters are not suitable for children who have the habit of eating before going to bed to take in the morning and are not compatible with children's morning digestion conditions.

[0004] The technical solution adopted in the present invention is as follows:

[0005] A two-component complex formula for promoting growth in children, comprising a leading agent and a main agent;

[0006] The precursor comprises a sustained-release short-chain fatty acid precursor, L-glutamine microcapsules wrapped in galacto-oligosaccharide, and a pH-sensitive chitosan carrier loaded with a 5-HT precursor;

[0007] The main agents include calcium-VD3-collagen peptide self-assembled nanoparticles and Zn-Mg-vitamin K2 hydrogel microspheres;

[0008] The lead dose is taken 45-60 minutes before the main dose.

[0009] A method for preparing a two-component compound formula for promoting growth in children comprises the following steps:

[0010] S1. Preparation of leading agent

[0011] S1.1. Prepare sustained-release short-chain fatty acid precursors, L-glutamine microcapsules coated with galacto-oligosaccharides, and trace amounts of 5-HT precursors loaded on pH-sensitive chitosan carriers;

[0012] S1.2, 80-85 parts by weight of a sustained-release short-chain fatty acid precursor, 120-122 parts by weight of L-glutamine microcapsules coated with oligogalactose, and 3-5 parts by weight of a 5-HT precursor loaded on a pH-sensitive chitosan carrier are mixed, followed by addition of tricalcium phosphate and tocopherol, and the mixture is three-dimensionally mixed and then freeze-dried to obtain a precursor, which is a powder;

[0013] S2. Preparation of main agent

[0014] S2.1, prepare calcium-VD3-collagen peptide self-assembled nanoparticles and Zn-Mg-vitamin K2 hydrogel microspheres respectively;

[0015] S2.2, preparing a core material by mixing calcium-VD3-collagen peptide self-assembled nanoparticles and Zn-Mg-vitamin K2 hydrogel microspheres;

[0016] S2.3. Combine the core material with the capsule wall material to prepare a capsule-type main agent;

[0017] S3. Independent packaging: The precursor is packed in an aluminum foil bag filled with nitrogen; the main agent is packaged using blister packaging technology.

[0018] Furthermore, the S3, independent packaging: the leading agent is packed in an aluminum foil bag filled with nitrogen, with a quantity of 3.0g±0.1g per bag; the main agent is packaged using blister packaging technology, and the dosage of the capsule-type main agent is 3.5g±0.1g / pill; when used in combination, 1-2 bags of leading agent are used together with 2 capsules of the main agent per day.

[0019] Furthermore, the sustained-release short-chain fatty acid precursor is butyrate starch, and the preparation method is:

[0020] A1. Mix potato starch and butyric anhydride, add lipase, and react at 50°C for 5-6 hours to obtain crude butyrate starch; wherein the mass ratio of potato starch to butyric anhydride is 50:1;

[0021] A2. The crude butyrate starch is spray-coated with an azo polymer using a fluidized bed spray method and then dried to obtain a sustained-release short-chain fatty acid precursor.

[0022] Furthermore, the L-glutamine microcapsules coated with galactoligosaccharides are prepared by the following method: dissolving galactoligosaccharides in 50°C pure water, adding L-glutamine, and homogenizing to obtain a mixed solution; spray-drying the mixed solution with an inlet air temperature of 60°C and an outlet air temperature of 40°C to obtain L-glutamine microcapsules coated with galactoligosaccharides; wherein the mass ratio of galactoligosaccharides to L-glutamine is 2:1.

[0023] Furthermore, the pH-sensitive chitosan carrier-loaded trace 5-HT precursor is prepared by the following method: dissolving chitosan in acetic acid solution, adding 5-HTP, stirring evenly by magnetic stirring, and then slowly adding sodium tripolyphosphate solution, adjusting the pH to 8.5 for cross-linking, collecting microspheres by centrifugation, and freeze-drying to obtain the pH-sensitive chitosan carrier-loaded trace 5-HT precursor; wherein the mass ratio of chitosan to 5-HTP is 2:1.

[0024] Furthermore, the surface of the calcium-VD3-collagen peptide self-assembled nanoparticles is modified by a gum arabic-tannic acid complex. The preparation method is as follows: fish scale collagen peptide is dissolved in a PBS buffer solution with a pH of 7.4, tricalcium citrate and VD3 are added, and a nanoparticle suspension is formed after ultrasonic homogenization. The nanoparticle suspension is fluidized bed and sprayed with a gum arabic-tannic acid complex for surface modification. After pre-freezing to -40°C, the suspension is vacuum dried at -50°C for 24 hours to obtain calcium-VD3-collagen peptide self-assembled nanoparticles.

[0025] Furthermore, the Zn-Mg-vitamin K2 hydrogel microspheres are prepared by the following method: adding Zn-glycine chelate and Mg-yeast powder to a sodium alginate solution, mixing evenly, adding vitamin K2 liposomes, and continuing to stir and mix to obtain a mixed solution; dropping the mixed solution into a CaCl2 solution for solidification to form hydrogel microspheres, then immersing the microspheres in a chitosan acetic acid solution for coating, filtering, and vacuum drying at -50°C to obtain Zn-Mg-vitamin K2 hydrogel microspheres.

[0026] Furthermore, the mass ratio of gum arabic to tannic acid in the gum arabic-tannic acid complex is 10:1.

[0027] Furthermore, the contents of calcium, VD3, Zn, Mg and vitamin K2 in each capsule-type main agent are 250-300 mg / capsule, 5-7.5 μg / capsule, 3-4 mg / capsule, 50-70 mg / capsule and 25-35 μg / capsule respectively.

[0028] Furthermore, the method of using the lead agent and the main agent is: the lead agent is dispersed in the dairy product and taken 45-60 minutes before the main agent.

[0029] The present invention is mainly suitable for children aged 6-7 years old, who are in the golden period of growth and have mature spleen and stomach systems.

[0030] In summary, due to the adoption of the above technical solution, the beneficial effects of the present invention are:

[0031] 1. A method for preparing a two-component complex formula for promoting growth in children comprises a two-component substance comprising a lead agent and a main agent, which are taken separately. The lead agent is first taken together with dairy products. The lead agent simultaneously forms a triple activation component through a sustained-release short-chain fatty acid precursor, L-glutamine microcapsules wrapped in oligogalactose, and a trace 5-HT precursor loaded on a pH-sensitive chitosan carrier, thereby achieving triple activation (activation → peristaltic nerves, activation → digestive enzymes, activation → smooth muscles), targeted activation of the digestive tract function of children in the morning, providing a digestive activation reaction environment for the main agent, and promoting the absorption of the main agent. The main agent in this application provides growth-promoting substances such as proteins, minerals, and vitamins. Under the digestive conditions created by the lead agent, the above-mentioned growth-promoting substances are significantly more effective than those taken directly in the prior art.

[0032] 2. The lead agent in the two-component formulation of the present invention is a powder that can be taken together with dairy products (milk, milk powder), similar to the existing administration method. On this basis, although the present invention requires the main agent to be taken in stages, the main agent is in the form of capsules, which is easy to carry and take, and is suitable for students. It is convenient to take even at school without causing any inconvenience.

[0033] 3. The two components of the present invention are taken at different time periods to avoid the intake of large amounts of growth-promoting nutrients during periods of weak digestion and metabolism, thereby effectively reducing ineffective loss of nutrients. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for use in the embodiments. It should be understood that the following drawings only illustrate certain embodiments of the present invention and should not be considered as limiting the scope. A person of ordinary skill in the art can also derive other relevant drawings based on these drawings without inventive effort, among which:

[0035] Figure 1 It is a local correlation diagram between the various components in the leading agent of the present invention;

[0036] Figure 2 It is a correlation diagram between the leading agent and the main agent of the present invention. DETAILED DESCRIPTION

[0037] In order to make the objectives, technical solutions, and advantages of the present invention more clearly understood, the present invention is further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only intended to explain the present invention and are not intended to limit the present invention. That is, the embodiments described herein are only some embodiments of the present invention, not all embodiments. Generally, the components of the embodiments of the present invention described and illustrated in the drawings herein may be arranged and designed in various different configurations.

[0038] The following detailed description of the embodiments of the application provided in the accompanying drawings is not intended to limit the scope of the application claimed, but merely represents selected embodiments of the application. Based upon the embodiments of the application, all other embodiments that a person skilled in the art obtains without creative effort are within the scope of the application.

[0039] It should be noted that the relational terms herein such as first and second and the like are used solely to distinguish one entity or action from another, without necessarily requiring or implying any actual relationship or order between such entities or actions. Moreover, the terms "comprises", "comprising", or any other variations thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but can also include other elements not expressly listed or inherent to such process, method, article, or apparatus. Without further limitation, an element preceded by "comprises a" does not, without more limitations, foreclose the existence of additional identical elements in the process, method, article, or apparatus that comprises the recited element.

[0040] The features and performances of the application are further described in detail below in conjunction with the embodiments.

[0041] Embodiment 1

[0042] The preparation method of a child growth-promoting dual-component complex formula provided by the preferred embodiment of the application, the dual-component complex comprising a leading agent and a main agent, comprises the following steps:

[0043] S1, preparing the leading agent

[0044] S1.1, respectively preparing a slow-release short-chain fatty acid precursor, oligogalactose-coated L-glutamine microcapsules, and a pH-sensitive chitosan carrier loaded with a trace amount of 5-HT precursor;

[0045] S1.2, mixing 80 parts by weight of the slow-release short-chain fatty acid precursor, 120 parts by weight of the oligogalactose-coated L-glutamine microcapsules, and 3 parts by weight of the pH-sensitive chitosan carrier loaded with the 5-HT precursor, then adding tricalcium phosphate and tocopherol, three-dimensionally mixing them uniformly, and then freeze-drying to obtain the leading agent, which is a powder; the amount of tricalcium phosphate added is 0.5% of the total mass of the slow-release short-chain fatty acid precursor, the oligogalactose-coated L-glutamine microcapsules, and the pH-sensitive chitosan carrier loaded with the trace amount of 5-HT precursor, and the amount of tocopherol added is 0.1% of the total mass of the slow-release short-chain fatty acid precursor, the oligogalactose-coated L-glutamine microcapsules, and the pH-sensitive chitosan carrier loaded with the trace amount of 5-HT precursor; Figure 1It is a local correlation diagram between the various components in the precursor of the present invention;

[0046] S2. Preparation of main agent

[0047] S2.1, prepare calcium-VD3-collagen peptide self-assembled nanoparticles and Zn-Mg-vitamin K2 hydrogel microspheres respectively;

[0048] S2.2, preparing a core material by mixing calcium-VD3-collagen peptide self-assembled nanoparticles and Zn-Mg-vitamin K2 hydrogel microspheres;

[0049] S2.3. Combine the core material with the capsule wall material to prepare a capsule-type main agent, wherein the components of the capsule wall material mainly include gelatin and glycerin, and the capsule wall material is the existing gelatin capsule shell;

[0050] S3. Independent packaging: The precursor is packed in an aluminum foil bag filled with nitrogen; the main agent is packaged using blister packaging technology.

[0051] Said S3, independent packaging: the leading agent is packed in an aluminum foil bag filled with nitrogen, with the amount of each bag being 3.0g±0.1g; the main agent is packaged using blister packaging technology, and the dosage of the capsule-type main agent is 3.5g±0.1g / capsule; when used in combination, 1 bag of leading agent is used together with 2 capsules of the main agent per day.

[0052] The relationship between the leading agent and the main agent of the present invention is shown in the figure Figure 2 As shown;

[0053] The slow-release short-chain fatty acid precursor is butyrate starch, and the preparation method is as follows:

[0054] A1. Mix potato starch and butyric anhydride, add lipase, and react at 50°C for 5-6 hours to obtain crude butyrate starch; wherein the mass ratio of potato starch to butyric anhydride is 50:1;

[0055] A2. The crude butyrate starch is spray-coated with an azo polymer using a fluidized bed spray method and dried to obtain a sustained-release short-chain fatty acid precursor. The azo polymer is the coating material and the crude butyrate starch is the coating object. The azo polymer is a diethylazobenzene (DVAB)-coupled hydroxyethyl methacrylate (HEMA)-methyl methacrylate (MMA)-methacrylic acid (MAA) azo copolymer.

[0056] The L-glutamine microcapsules wrapped with galactoligosaccharides are prepared by the following method: dissolving galactoligosaccharides in 50°C pure water, adding L-glutamine, and homogenizing to obtain a mixed solution; spray-drying the mixed solution with an inlet air temperature of 60°C and an outlet air temperature of 40°C to obtain L-glutamine microcapsules wrapped with galactoligosaccharides; wherein the mass ratio of galactoligosaccharides to L-glutamine is 2:1.

[0057] The pH-sensitive chitosan carrier-loaded trace 5-HT precursor is prepared by the following method: dissolving chitosan in an acetic acid solution, adding 5-HTP, stirring evenly with a magnetic stirrer, slowly adding a sodium tripolyphosphate solution dropwise, adjusting the pH to 8.5 for cross-linking, collecting microspheres by centrifugation, and freeze-drying to obtain the pH-sensitive chitosan carrier-loaded trace 5-HT precursor; wherein the mass ratio of chitosan to 5-HTP is 2:1.

[0058] The surface of the calcium-VD3-collagen peptide self-assembled nanoparticles is modified by a gum arabic-tannic acid complex. The preparation method comprises the following steps: dissolving fish scale collagen peptide in a PBS buffer solution with a pH of 7.4, adding tricalcium citrate and VD3, and performing ultrasonic homogenization to form a nanoparticle suspension. The nanoparticle suspension is subjected to surface modification by spraying the gum arabic-tannic acid complex on the suspension using a fluidized bed. The suspension is pre-frozen to -40°C and then vacuum-dried at -50°C for 24 hours to obtain the calcium-VD3-collagen peptide self-assembled nanoparticles.

[0059] The Zn-Mg-vitamin K2 hydrogel microspheres are prepared by the following method: adding Zn-glycine chelate and Mg-yeast powder to a sodium alginate solution, mixing them evenly, then adding vitamin K2 liposomes, and continuing to stir and mix to obtain a mixed solution; dropping the mixed solution into a CaCl2 solution for solidification to form hydrogel microspheres, then immersing the microspheres in a chitosan acetic acid solution for coating, filtering, and vacuum drying at -50°C to obtain the Zn-Mg-vitamin K2 hydrogel microspheres.

[0060] The mass ratio of gum arabic to tannic acid in the gum arabic-tannic acid complex is 10:1.

[0061] This embodiment is suitable for children aged 6-7 years old. The contents of calcium, VD3, Zn, Mg and vitamin K2 in each capsule-type main agent are 250-300 mg / capsule, 5-7.5 μg / capsule, 3-4 mg / capsule, 50-70 mg / capsule and 25-35 μg / capsule respectively.

[0062] The method of using the pre-initiator and the main agent is: the pre-initiator is dispersed in the dairy product and taken 45 minutes before the main agent.

[0063] Example 2

[0064] This embodiment is based on embodiment 1 and differs from embodiment 1 in that: in this embodiment S1, the leading agent is prepared

[0065] S1.1. Prepare sustained-release short-chain fatty acid precursors, L-glutamine microcapsules coated with galacto-oligosaccharides, and trace amounts of 5-HT precursors loaded on pH-sensitive chitosan carriers;

[0066] S1.2. Mix 83 parts by weight of a sustained-release short-chain fatty acid precursor, 121 parts by weight of L-glutamine microcapsules coated with galacto-oligosaccharides, and 4 parts by weight of a 5-HT precursor supported by a pH-sensitive chitosan carrier, then add tricalcium phosphate and tocopherol. Mix well in three dimensions and then freeze-dry to obtain a precursor, which is a powder. All other components remain the same.

[0067] Example 3

[0068] This embodiment is based on embodiment 1 and differs from embodiment 1 in that: in this embodiment S1, the leading agent is prepared

[0069] S1.1. Prepare sustained-release short-chain fatty acid precursors, L-glutamine microcapsules coated with galacto-oligosaccharides, and trace amounts of 5-HT precursors loaded on pH-sensitive chitosan carriers;

[0070] S1.2. Mix 85 parts by weight of a sustained-release short-chain fatty acid precursor, 122 parts by weight of L-glutamine microcapsules coated with galacto-oligosaccharides, and 5 parts by weight of a 5-HT precursor supported by a pH-sensitive chitosan carrier, then add tricalcium phosphate and tocopherol. Mix well in three dimensions and then freeze-dry to obtain a lead agent in the form of a powder. All other components remain the same.

[0071] Example 4

[0072] Based on Example 1, the difference from Example 1 is that: when used in combination, 2 bags of the lead agent are used together with 2 capsules of the main agent per day.

[0073] Example 5

[0074] Based on Example 1, the difference from Example 2 is that when used together, the leading agent and the main agent are used in the following manner: the leading agent is dispersed in the dairy product and taken 50 minutes before the main agent.

[0075] Example 6

[0076] Based on Example 1, the difference from Example 2 is that when used together, the leading agent and the main agent are used in the following manner: the leading agent is dispersed in the dairy product and taken 60 minutes before the main agent.

[0077] Comparative Example 1

[0078] Based on the preparation method and formula of Example 1, the children's growth-promoting component provided in this comparative example only includes the main agent but does not include the leading agent.

[0079] Comparative Example 2

[0080] Based on the preparation method and formulation of Example 1, the precursor in this comparative example does not include a sustained-release short-chain fatty acid precursor.

[0081] Comparative Example 3

[0082] Based on the preparation method and formulation of Example 1, the leading agent in this comparative example does not include L-glutamine microcapsules coated with galacto-oligosaccharides.

[0083] Comparative Example 4

[0084] Based on the preparation method and formulation of Example 1, the precursor in this comparative example does not include a trace amount of 5-HT precursor supported by a pH-sensitive chitosan carrier.

[0085] Comparative Example 5

[0086] Based on the preparation method and formula of Example 2, when used in conjunction with each other in this comparative example, 0.5 bags of the lead agent are taken daily together with 2 capsules of the main agent.

[0087] Comparative Example 6

[0088] Based on the preparation method and formula of Example 2, when used in conjunction with each other in this comparative example, 3 bags of the lead agent are taken daily together with 2 capsules of the main agent.

[0089] Comparative Example 7

[0090] Based on Example 1, in this comparative example, a sustained-release short-chain fatty acid precursor, L-glutamine microcapsules wrapped in oligogalactose, a trace amount of 5-HT precursor loaded on a pH-sensitive chitosan carrier, calcium-VD3-collagen peptide self-assembled nanoparticles, and Zn-Mg-vitamin K2 hydrogel microspheres are physically blended to obtain a complex, which is a children's growth-promoting composition.

[0091] Test Example 1

[0092] Growth promotion experiment in young rats: Animal model: Kunming male mice (weaned at 21 days, 10 mice per experimental group) were fed a basic feed + daily gavage of the growth-promoting composition of Examples 1-6 and Comparative Examples 1-7. The gavage method was based on the corresponding test groups (Examples 1-6 and Comparative Examples 1-7). The control group was given normal saline, and the gavage method was based on Example 1. The amount of the growth-promoting composition was calculated as the rat equivalent dose based on the average weight of 6-7 children and the weight of rats. The mice were gavaged for 7 days, and the weight gain and height gain of the 21-day weaned mice after gavage for 7 days were measured. The results are shown in Table 1.

[0093] Table 1 Growth promotion experiment results

[0094] Weight gain Height increase Example 1 ＞8g >2cm Example 2 ＞8g >2cm Example 3 ＞8g >2cm Example 4 ＞8g >2cm Example 5 ＞8.3g >2.2cm Example 6 ＞8g >2cm Comparative Example 1 6.2-6.5g 1-1.1cm Comparative Example 2 7.3-7.5g 1.3-1.6cm Comparative Example 3 7.5-7.7g 1.7-2cm Comparative Example 4 7.3-7.5g 1.3-1.5cm Comparative Example 5 7.5-7.8g 1.5-2cm Comparative Example 6 - (Digestive Disorders) - (Digestive Disorders) Comparative Example 7 6.4-6.7g 1-1.2cm control group 3.9-4.8g 0.7-0.9cm

[0095] Combined with the data in Table 1, it can be seen that the present invention has the effect of promoting growth.

[0096] Test Example 2

[0097] The leading agent and main agent prepared in Examples 1-3 and the complex in Comparative Example 7 were subjected to acute toxicity tests according to existing techniques. The test results are shown in Table 2.

[0098] Table 2 Acute toxicity test

[0099] Example 1 Example 2 Example 3 Comparative Example 7 Acute toxicity Safety Safety Safety Safety

[0100] The growth-promoting two-component composite prepared by the present invention is safe to use.

[0101] Test Example 3

[0102] Growth promotion experiment in young rats: Animal model: Kunming male mice (weaned at 21 days, 10 mice in each experimental group) were injected with equal doses of atropine to slow down intestinal peristalsis. 30 minutes after the injection of equal doses of atropine, they were gavaged with the leading agents in Examples 1-3 and normal saline in the control group. The dosage was referred to that in Experimental Example 1. 50 minutes after gavage, the mice were gavaged with ink to observe their defecation. The first defecation time in Examples 1-3 was earlier than that in the control group, and the amount of black stool in Examples 1-3 was greater than that in the control group within 4 hours; this proved that the leading agent of the present invention has the effect of activating digestive ability; in addition, among Examples 1-3, the first defecation time in Example 2 was the earliest, and compared with Examples 1 and 3, the group distribution of Example 2 was better.

[0103] The above description is only a preferred embodiment of the present invention and is not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions and improvements made by any technician familiar with the field within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A method for using a two-component compound for promoting growth in children, characterized in that: The child growth-promoting two-component complex comprises a leading agent and a main agent; The precursor comprises 83 parts by weight of a sustained-release short-chain fatty acid precursor, 121 parts by weight of L-glutamine microcapsules wrapped in oligosaccharides, and 4 parts by weight of a pH-sensitive chitosan carrier loaded with a 5-HT precursor; the sustained-release short-chain fatty acid precursor is starch butyrate; and the 5-HT precursor is 5-HTP; The main agents include calcium-VD3-collagen peptide self-assembled nanoparticles and Zn-Mg-vitamin K2 hydrogel microspheres; The lead agent is taken 50 minutes before the main agent; The dosage of the lead agent in each bag is 3.0g±0.1g, and the dosage of the capsule-type main agent is 3.5g±0.1g / capsule; when used in combination, 1-2 bags of lead agent are taken together with 2 capsules of the main agent per day; the content of calcium, VD3, Zn, Mg and vitamin K2 in each capsule-type main agent are 250-300mg / capsule, 5-7.5μg / capsule, 3-4mg / capsule, 50-70mg / capsule and 25-35μg / capsule respectively.

2. The method for using the two-component compound for promoting growth in children according to claim 1, characterized in that: The preparation method of the children's growth-promoting two-component complex comprises the following steps: S1. Preparation of leading agent S1.

1. Prepare sustained-release short-chain fatty acid precursors, L-glutamine microcapsules coated with galacto-oligosaccharides, and 5-HT precursors loaded on pH-sensitive chitosan carriers; S1.

2. 83 parts by weight of a sustained-release short-chain fatty acid precursor, 121 parts by weight of L-glutamine microcapsules coated with galacto-oligosaccharides, and 4 parts by weight of a pH-sensitive chitosan carrier loaded with 5-HT precursor were mixed, tricalcium phosphate and tocopherol were added, and the mixture was uniformly mixed in three dimensions and then freeze-dried to obtain a precursor, which was a powder. S2. Preparation of main agent S2.1, prepare calcium-VD3-collagen peptide self-assembled nanoparticles and Zn-Mg-vitamin K2 hydrogel microspheres respectively; S2.2, preparing a core material by mixing calcium-VD3-collagen peptide self-assembled nanoparticles and Zn-Mg-vitamin K2 hydrogel microspheres; S2.

3. Combine the core material with the capsule wall material to prepare a capsule-type main agent; S3. Independent packaging: The precursor is packed in an aluminum foil bag filled with nitrogen; the main agent is packaged using blister packaging technology.

3. The method for using the two-component compound for promoting growth in children according to claim 2, characterized in that: Said S3, independent packaging: the leading agent is packed in an aluminum foil bag filled with nitrogen, with a quantity of 3.0g±0.1g per bag; the main agent is packed using blister packaging technology, with a dosage of 3.5g±0.1g per capsule of the main agent.

4. The method for using the two-component compound for promoting growth in children according to claim 2, characterized in that: The slow-release short-chain fatty acid precursor is butyrate starch, and the preparation method is as follows: A1. Mix potato starch and butyric anhydride, add lipase, and react at 50°C for 5-6 hours to obtain crude butyrate starch; wherein the mass ratio of potato starch to butyric anhydride is 50:1; A2. The crude butyrate starch is spray-coated with an azo polymer using a fluidized bed spray method and then dried to obtain a sustained-release short-chain fatty acid precursor.

5. The method for using the two-component compound for promoting growth in children according to claim 2, characterized in that: The L-glutamine microcapsules wrapped with galactoligosaccharides are prepared by the following method: dissolving galactoligosaccharides in 50°C pure water, adding L-glutamine, and homogenizing to obtain a mixed solution; spray-drying the mixed solution with an inlet air temperature of 60°C and an outlet air temperature of 40°C to obtain L-glutamine microcapsules wrapped with galactoligosaccharides; wherein the mass ratio of galactoligosaccharides to L-glutamine is 2:

1.

6. The method for using the two-component compound for promoting growth in children according to claim 2, characterized in that: The pH-sensitive chitosan carrier-loaded trace 5-HT precursor is prepared by the following method: dissolving chitosan in an acetic acid solution, adding 5-HTP, stirring evenly with a magnetic stirrer, slowly adding a sodium tripolyphosphate solution dropwise, adjusting the pH to 8.5 for cross-linking, collecting microspheres by centrifugation, and freeze-drying to obtain the pH-sensitive chitosan carrier-loaded trace 5-HT precursor; wherein the mass ratio of chitosan to 5-HTP is 2:

1.

7. The method for using the two-component compound for promoting growth in children according to claim 2, characterized in that: The Zn-Mg-vitamin K2 hydrogel microspheres are prepared by the following method: adding Zn-glycine chelate and Mg-yeast powder to a sodium alginate solution, mixing them evenly, then adding vitamin K2 liposomes, and continuing to stir and mix to obtain a mixed solution; dropping the mixed solution into a CaCl2 solution for solidification to form hydrogel microspheres, then immersing the microspheres in a chitosan acetic acid solution for coating, filtering, and vacuum drying at -50°C to obtain the Zn-Mg-vitamin K2 hydrogel microspheres.

Images